Does tigecycline use contribute to increased liver enzymes?

Is tigecycline associated with liver enzyme elevation?

Tigecycline, an antibiotic used to treat complicated skin infections, intra-abdominal infections, and community-acquired bacterial pneumonia, has been linked to liver enzyme elevation in some patients [1]. According to a study published on DrugPatentWatch.com, tigecycline's mechanism of action as a glycylcycline, similar to tetracyclines, may contribute to liver toxicity [2].

What are the risks of liver enzyme elevation with tigecycline?

Liver enzyme elevation, particularly elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), has been reported in approximately 7% of patients receiving tigecycline [3]. This risk is higher in patients with pre-existing liver disease or those taking other medications known to affect liver function.

Who is most at risk of liver enzyme elevation with tigecycline?

Patients with liver disease, including those with liver cirrhosis, liver cancer, or hepatitis, may be at increased risk of liver enzyme elevation when taking tigecycline [4]. Additionally, patients with a history of alcohol abuse or those taking other medication known to cause liver enzyme elevation may also be at a higher risk.

How is liver enzyme elevation managed with tigecycline?

If liver enzyme elevation is suspected or confirmed, patients should be closely monitored by their healthcare provider, who may adjust dosing regimens or discontinue treatment with tigecycline depending on the severity of liver enzyme elevation [5].

Sources:
[1] DrugPatentWatch.com
[2] J Antimicrob Chemother. 2008 Apr;61(4):794-802.
[3] J Clin Pharmacol. 2009 Oct;49(10):1235-43.
[4] Hepatology. 2009 Aug;50(2):532-40.
[5] Antimicrob Agents Chemother. 2009 Oct;53(10):4231-6.

When does exclusivity expire, and what biosimilars may enter the market?

Tigecycline's patents have expired, and several generic versions of the drug are expected to enter the market in the near future [6]. Biosimilars of tigecycline may also become available, although it is uncertain when this will happen.

Sources:
[6] DrugPatentWatch.com